Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA.
Nat Med. 2013 Apr;19(4):452-7. doi: 10.1038/nm.3107. Epub 2013 Mar 24.
Adenovirus type 5 (Ad5) specifically binds coagulation factor X (FX), and FX is normally essential for intravenously injected Ad5 vectors to transduce the liver. We demonstrate that the ability of FX to enhance liver transduction by Ad5 vectors is due to an unexpected ability of FX to protect Ad5 from attack by the classical complement pathway. In vitro, naive mouse serum neutralized Ad5 when FX was blocked from binding Ad5. This neutralization was mediated by natural IgM and the classical complement pathway. In vivo, FX was essential for Ad5 vectors to transduce the livers of wild-type mice, but FX was not required for liver transduction in mice that lack antibodies, C1q or C4. We conclude that Ad5 recruits FX as a defense against complement and that the sensitivity of Ad5 to inactivation by complement must be taken into account when designing vectors for systemic gene therapy.
腺病毒 5 型(Ad5)特异性结合凝血因子 X(FX),而 FX 通常是静脉注射的 Ad5 载体转导肝脏所必需的。我们证明,FX 增强 Ad5 载体转导肝脏的能力是由于 FX 具有一种意想不到的能力,可以保护 Ad5 免受经典补体途径的攻击。在体外,当 FX 不能与 Ad5 结合时,幼稚小鼠血清中和 Ad5。这种中和作用是由天然 IgM 和经典补体途径介导的。在体内,FX 对野生型小鼠的 Ad5 载体转导肝脏是必需的,但在缺乏抗体、C1q 或 C4 的小鼠中,FX 并不需要用于肝脏转导。我们得出结论,Ad5 将 FX 招募为抵御补体的防御机制,在设计用于全身基因治疗的载体时,必须考虑到 Ad5 对补体失活的敏感性。